Dr. Lesokhin on the Utility of Elranatamab in Relapsed/Refractory Multiple Myeloma


Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.

Alexander M. Lesokhin, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the utility of elranatamab (PF-06863135) in the ongoing phase 2 MagnetisimMM-3 trial (NCT04649359) in relapsed/refractory multiple myeloma.

Elranatamab is a BCMA-directed bispecific antibody that binds to specific moieties: BCMA on the myeloma cells and CD-3 on immune cells, Lesokhin says. The agent elicits a cell-killing effect by activating the T-cells in the vicinity of the myeloma cells. 

Subcutaneously administered elranatamab was evaluated in the phase 1 dose-escalation MagnetisMM-1 trial (NCT03269136). The results of the trial demonstrated efficacy with a 215 µg/kg dose of the bispecific antibody in patients with relapsed/refractory multiple myeloma. Moreover, an overall response rate of 70% was observed among 20 patients who received at least 215 μg/kg of elranatamab, Lesokhin notes.

Moreover, among patients treated above the dose threshold, 4 received prior BCMA-directed therapy, including CAR T-cell therapy or an antibody-drug conjugate. Of those patients, 3 responded to elranatamab, suggesting that sequential administration of BCMA-directed therapies is a potential treatment strategy that can be employed in this patient population, Lesokhin concludes.

Related Videos
Robert Huddart, PhD, leader, Clinical Academic Radiotherapy Team, The Institute of Cancer Research; professor, urological cancer, honorary consultant, Urological Oncology, The Royal Marsden NHS Foundation Trust
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine